Envisia Therapeutics

Envisia Therapeutics, founded in 2013, is a private biotechnology company focused on developing novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT platform to develop treatments for various ocular diseases, with the most advanced being ENV515 for the treatment of glaucoma. ENV515 is a novel sustained-release formulation of a prostaglandin analog. It has the potential to significantly limit disease progression and vision loss by improving product performance and patient compliance.